Open AccessFAVIPIRAVIR AS A POTENTIAL DRUG IN THE TREATMENT OF COVID-19
Author(s) -
Dany Geraldo Kramer,
Maria Josilene Leonardo Da Silva,
Gislanne Stéphanne Estevam da Silva,
Ana Maria Marinho Andrade de Moura,
Geraldo Barroso Cavalcanti,
Anésio Mendes de Sousa,
Ana Elizabeth Alves da Silva
Publication year - 2020
Publication title -
international journal of research - granthaalayah
Language(s) - English
Resource type - Journals
eISSN - 2394-3629
pISSN - 2350-0530
DOI - 10.29121/granthaalayah.v8.i4.2020.2
Subject(s) - favipiravir , drug , pneumonia , virology , medicine , antiviral drug , intensive care medicine , covid-19 , clinical trial , pharmacology , infectious disease (medical specialty) , disease
Favipiravir is a drug developed for use against influenza and has been used successfully in other infectious conditions. After being internalized in the cell, the substance is phosphoribosylated acting on the RNA polymerase, and thus inhibiting replication and RNA viruses. Thus, the present study aimed to discuss the potential use of favipiravir in coronovavirus infections. There have been few studies involving favipiravir in COVID 19, however there is a report of recovery in more than 70% of patients diagnosed with pneumonia. However, new studies need to be carried out, mainly randomized clinical trials, so that the potential use of favipiravir in coronoviruses is adequately grounded.